77 Quick summary: An international single-cell sequencing and spatial transcriptomics study has produced an unprecedentedly detailed cellular atlas of meningioma, demonstrating that the surrounding immune cell ecosystem plays a decisive role in driving brain tumour growth and post treatment recurrence. Researchers mapped over five hundred thousand individual cells to reveal distinct myeloid cell states that strongly correlate with either benign or highly aggressive disease trajectories, providing far greater predictive power than traditional clinical grading frameworks. These breakthrough findings hold profound implications for healthcare practice and public policy, offering a non invasive molecular classification tool that allows clinical professionals to tailor aggressive interventions precisely, eliminate unnecessary overtreatment, and protect the long-term physiological well-being of tens of thousands of patients annually. A groundbreaking study has produced one of the most detailed maps yet of meningioma, the most common brain tumour in adults, showing how the tumour’s surrounding environment influences disease behaviour and patient outcomes. The study, published in Nature Genetics, was led by scientists at the Mayo Clinic in collaboration with colleagues at the Princess Margaret Cancer Centre. It combines single-cell sequencing and spatial transcriptomics to examine tumours at unprecedented resolution. An estimated 30,000–40,000 people in the US are diagnosed with meningioma annually. While many are benign and grow slowly, others recur or become aggressive, making accurate risk prediction a longstanding challenge. Traditional grading systems often fail to fully capture this complex behaviour, driving efforts to develop molecular classification tools that better predict recurrence after surgery. The new study advances this field by analysing signals from individual cells rather than bulk tumour tissue, highlighting the critical role of the tumour microenvironment — the mix of immune and support cells around the tumour. “We’re seeing that it’s not just the tumour cells themselves but the ecosystem around them that influences how these tumours grow and respond to treatment,” .says Dr Gelareh Zadeh, a neurosurgeon at the Mayo Clinic and senior author of the study. Researchers analysed hundreds of tumour samples, mapping more than 500,000 individual cells and generating millions of data points. By integrating single-nuclear RNA sequencing, spatial transcriptomics, and other data from a large cohort, the study provides a comprehensive view of neoplastic and non-neoplastic cells in meningioma biology. This high-resolution atlas reveals genetic differences between aggressive and benign tumours, how cells evolve spatially, and their interactions within the local environment. “Instead of looking at the tumour as a whole, we can now break it down into its individual components and understand what is driving its behaviour,” says Zadeh. The team identified distinct states of immune cells, especially myeloid cells, that vary by tumour type. Certain states correlate with more aggressive disease, while others link to better patient outcomes. The findings extend earlier Mayo Clinic work on molecular classification for meningioma. Specific immune cell programmes strongly associate with post-treatment recurrence risk and, in some instances, enhance the predictive power of both traditional tumour grade and modern molecular systems. This could refine choices around surgery, radiation therapy, or intensified monitoring. The biological signatures may also appear in blood-based biomarkers, offering potential for non-invasive monitoring without repeated surgery. “This moves us closer to a future where we can better stratify patients — identifying who needs more aggressive therapy and who may avoid overtreatment,” says Zadeh. The research also uncovers potential therapeutic targets by detailing communication between immune and tumour cells. Disrupting these pathways might slow tumour growth or improve treatment responses. Next steps involve validation in larger, multicentre groups and development of clinical tools and trials based on these insights.